Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or Viridian Therapeutics, Inc.

Biotech Giants: Who Manages SG&A Costs Better?

__timestampDynavax Technologies CorporationViridian Therapeutics, Inc.
Wednesday, January 1, 2014177630007751000
Thursday, January 1, 20152218000010251000
Friday, January 1, 2016372570009575000
Sunday, January 1, 20172736700010912000
Monday, January 1, 20186477000011049000
Tuesday, January 1, 20197498600011646000
Wednesday, January 1, 20207925600013265000
Friday, January 1, 202110015600025805000
Saturday, January 1, 202213140800035182000
Sunday, January 1, 202315294600094999000
Loading chart...

Unleashing insights

Optimizing SG&A Costs: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Dynavax Technologies Corporation and Viridian Therapeutics, Inc. have shown contrasting approaches to SG&A optimization. From 2014 to 2023, Dynavax's SG&A expenses surged by over 760%, peaking at approximately $153 million in 2023. In contrast, Viridian's expenses grew by about 1,125%, reaching nearly $95 million in the same year. Despite Viridian's higher growth rate, Dynavax consistently spent more, indicating a potentially aggressive expansion strategy. This data highlights the importance of strategic cost management in sustaining growth and competitiveness in the biotech sector. As these companies continue to evolve, their ability to optimize SG&A costs will be pivotal in determining their long-term success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025